Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at initiated coverage on shares of Check-Cap (NASDAQ:CHEKFree Report) in a research note published on Friday morning. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

NASDAQ CHEK opened at $2.18 on Friday. The company has a market capitalization of $12.75 million, a P/E ratio of -0.72 and a beta of 0.45. Check-Cap has a 12-month low of $1.41 and a 12-month high of $4.63. The firm has a 50-day moving average price of $2.29 and a two-hundred day moving average price of $2.42.

Check-Cap Company Profile

(Get Free Report)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Featured Stories

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with's FREE daily email newsletter.